IDEAYA Biosciences

7000 Shoreline Court
Suite 350
South San Francisco
California
94080
United States

Tel: 650-443-6209

About IDEAYA Biosciences

Founded in 2015, IDEAYA Biosciences is a public, clinical-stage synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using DNA sequencing and other molecular diagnostics. Our approach integrates extensive capabilities in identifying and validating translational biomarkers with small molecule drug discovery to select patient populations most likely to benefit from the therapies we are developing. We are applying these capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality – which represents an emerging class of precision medicine targets. We believe this diversified approach will enable us to deliver the right medicine to the right patient to drive a more robust clinical response.

Stock Symbol: IDYA

136 articles with IDEAYA Biosciences

IDEAYA Biosciences Announces IDE196 Monotherapy Phase 2 Dose Selection and Clinical Program Update

3/18/2020

IDEAYA Biosciences, Inc., an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announces an update for IDE196, a Protein Kinase C inhibitor, in its ongoing Phase 1/2 clinical trial entitled "A Phase 1/2 Study in Patients with Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions".
IDEAYA and Pfizer Enter Clinical Trial Collaboration and Supply Agreement to Evaluate Clinical Combination of IDE196 and Binimetinib in Solid Tumors Harboring GNAQ or GNA11 Hotspot Mutations

3/18/2020

Clinical combination of IDE196, a PKC inhibitor, and binimetinib, a MEK inhibitor, to be investigated in patients with solid tumors that harbor GNAQ or GNA11 hotspot mutations, including Metastatic Uveal Melanoma, Cutaneous Melanoma, and Colorectal Cancer
IDEAYA Biosciences and Cancer Research UK Announce Expanded Research Collaboration for PARG, a DDR-Based Synthetic Lethality Target, Evaluating DNA Replication Vulnerabilities

3/11/2020

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, today announced an expanded research collaboration with Cancer Research UK and the University of Manchester, UK, to develop small molecule inhibitors of Poly(ADP-ribose) glycohydrolase (PARG).
IDEAYA Biosciences Announces Synthetic Lethality Research Highlights and Target Milestones for 2020

1/15/2020

Chief Executive Officer Yujiro Hata will present key research highlights on Synthetic Lethality today, January 15, 2020, at 5:00 pm PT (8:00 pm ET) at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco
IDEAYA Biosciences and Boston Children's Hospital Collaborate on Preclinical Evaluation of IDE196 for Sturge Weber Syndrome - a Rare Disease Associated with Genetic Mutation of GNAQ

1/10/2020

IDEAYA Biosciences, Inc. announced that the company has entered into a Sponsored Research Agreement with Boston Children's Hospital for preclinical evaluation of the role of protein kinase C in Sturge Weber syndrome, a rare neurocutaneous disorder characterized by capillary malformations and associated with mutations in GNAQ.
IDEAYA Biosciences to Present at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2020

1/6/2020

IDEAYA Biosciences, Inc. announced that the company is scheduled to present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 15, 2020 at 5:00 p.m. PT.
IDEAYA Biosciences Appoints Wendy Yarno to its Board of Directors

12/18/2019

IDEAYA Biosciences, Inc., an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announced the appointment of Wendy L. Yarno as a Director of its Board of Directors..
IDE196 Program Updates: Targeting Initiation of Potentially Registration-Enabling Phase 2 Single-Arm Monotherapy Trial in MUM and Introduction of Tablet Formulation in Q1 2020

12/9/2019

Targeting initiation of Phase 2 single-arm potentially registration-enabling clinical trial in MUM in Q1 2020, potentially coinciding with Phase 2 introduction of tablet formulation
Phase 1/2 Clinical Trial Data for IDE196 Presented at Society for Melanoma Research Congress

11/20/2019

IDEAYA Biosciences, Inc. (Nasdaq: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announced it has presented data from an ongoing Phase 1/2 clinical trial entitled "A Phase 1/2 Study in Patients with Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions"
Phase 1/2 Clinical Trial Progress for IDE196 to be Presented at Society for Melanoma Research Congress

11/15/2019

Update on Phase 1 Dose-Escalation portion of ongoing Phase 1/2 clinical trial, with specific focus on dosing schema, patient enrollment, and safety data, to be presented at SMR on November 20, 2019
IDEAYA Biosciences, Inc. Reports Third Quarter 2019 Financial Results and Provides Business Update

11/13/2019

Single-arm Phase 2 clinical trial may be adequate to support an NDA seeking Accelerated Approval for IDE196 monotherapy in metastatic uveal melanoma (MUM)
IDEAYA Biosciences Announces Leadership Updates in Research Organization

11/5/2019

IDEAYA Biosciences, Inc. announced that Dr. Paul A. Barsanti, Ph.D., has joined IDEAYA as Vice President, Head of Drug Discovery, to help advance the company's ongoing preclinical research programs.
IDEAYA Biosciences Reports End‑of‑Phase 1 Meeting with FDA for IDE196 Confirms Acceptability of Single-Arm Trial Design for Potential Phase 2 Registration-Enabling Study in Metastatic Uveal Melanoma

10/31/2019

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics, provided a regulatory and clinical update on IDE196 following receipt of meeting minutes from an End‑of‑Phase 1 (EOP1) meeting with the FDA.
IDEAYA Biosciences to Present at Upcoming Investor Conferences

10/25/2019

IDEAYA Biosciences, Inc., an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics, announced that the company is scheduled to present in the following investor conferences
IDEAYA Announces First Patient Dosing of IDE196 for Solid Tumors outside of Uveal Melanoma and a Collaboration with Foundation Medicine in support of its Tumor-Agnostic GNAQ/11 Basket Trial

10/8/2019

IDEAYA Biosciences, Inc. announces it has dosed its first patient with cutaneous melanoma harboring a GNAQ or GNA11 mutation, a key milestone for evaluating Protein Kinase C inhibitor IDE196 in solid tumors outside of metastatic uveal melanoma as part of IDEAYA's ongoing Phase 1/2 clinical trial entitled "Patients with Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions".
IDEAYA Biosciences, Inc. Reports Second Quarter 2019 Financial Results and Provides Business Update

8/12/2019

IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics, provided a business update and announced financial results for the second quarter ended June 30, 2019.
IDEAYA Biosciences Announces First Patient Dosing of PKC inhibitor IDE196 in Phase 1/2 Tissue-Type Agnostic Basket Trial for Solid Tumors Harboring GNAQ or GNA11 Mutations

7/11/2019

IDEAYA Biosciences, Inc., an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announces initiation of its Phase 1/2 study evaluating IDE196 in Patients with Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions.
IDEAYA Biosciences Strengthens Management with Internal Appointments of Paul Stone, J.D., as Chief Financial Officer, Andres Ruiz Briseno, C.P.A., as Vice President, Finance, and Mick O'Quigley, M.B.A, as Vice President, Development Operations

7/9/2019

IDEAYA Biosciences, Inc., an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announced the promotions of Paul A. Stone, J.D., as Chief Financial Officer, Andres Briseno, C.P.A., as Vice President, Finance, and Mick O'Quigley, M.B.A., as Vice President, Development Operations.
IDEAYA Biosciences Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

5/28/2019

IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced the closing of its initial public offering of 5,750,000 shares of common stock at a public offering price of $10.00 per share.
IDEAYA Announces Pricing of Initial Public Offering

5/23/2019

IDEAYA Biosciences, Inc. announced the pricing of its initial public offering of 5,000,000 shares of common stock at a public offering price of $10.00 per share, before underwriting discounts and commissions.